High-throughput screening of stabilizers for respirator/syncytial virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles

Human Vaccines

Volumn 3, Issue 3, 2007, Pages 94-103

  Ausar, Salvador F ^a,c   Espina, Marianela ^a   Brock, Julie ^a   Thyagarayapuran, Nagarajan ^a   Repetto, Robert ^b   Khandke, Lakshmi ^b   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b WYETH RESEARCH   (United States)

^c Sanofi Pasteur   (Canada)

Author keywords

Absorption spectroscopy; Circular dichroism; Fluorescence spectroscopy; High throughput screening; Light scattering; Respiratory syncytial virus; Thermal stability; Vaccine formulation

Indexed keywords

AMINO ACID; POLYANION; POLYOL; SUGAR;

ARTICLE; CIRCULAR DICHROISM; EVALUATION; LIGHT SCATTERING; MEMBRANE FLUIDITY; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; THERMOSTABILITY; ULTRAVIOLET SPECTROSCOPY; VIRUS PARTICLE;

EID: 34248214194     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.3.4149     Document Type: Article

References (36)

1. Hall CB, Kopelman AE, Douglas Jr RG, Geiman JM, Meagher MP. Neonatal respiratory syncytial virus infection. N Engl J Med 1979; 300:393-6.
2. Hall CB. Prospects for a respiratory syncytial virus vaccine. Science 1994; 265:1393-4.
3. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003; 143:S127-32.
4. Falsey AR. Respiratory syncytial virus infection in elderly and high-risk adults, Exp Lung Res 2005; 31:77.
5. Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000; 25:751-5.
6. Ogra PL. Respiratory syncytial virus: The virus, the disease and the immune response. Paediatr Respir Rev 2004; 5(Suppl A):S119-26.
7. Walsh EE, Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein. J Virol 1983; 47:171-7.
8. Feldman SA, Hendry RM, Beeler JA Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 1999; 73:6610-7.
9. Ghildyal R, Mills J, Murray M, Vardaxis N, Meanger J. Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells. J Gen Virol 2002; 83:753-7.
10. Marty A, Meanger J, Mills J, Shields B, Ghildyal R. Association of matrix protein of respiratory syncytial virus with the host cell membrane of infected cells. Arch Virol 2004; 149:199-210.
11. Yu Q, Hardy RW, Wertz GW. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol 1995; 69:2412-9.
12. Crowe Jr JE. Respiratory syncytial virus vaccine development. Vaccine 2001; 20:S32-7.
13. Englund J. In search of a vaccine for respiratory syncytial virus: The saga continues. J Infect Dis 2005; 191:1036-9.
14. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
15. Collins PL, Murphy BR. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005; 2:166-73.
16. Zeng RH, Gong W, Fan CF, Wang YF, Mei XG. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope. Vaccine 2006; 24:941-7.
17. Vaughan K, Rhodes GH, Gershwin LJ. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 2005; 23:2928-42.
18. Olszewska W, Suezer Y, Sutter G, Openshaw PJ. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 2004; 23:215-21.
19. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104.
20. Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34:1649-53.
21. Chanock RM, Parrott RH, Vargosko AJ, Kapikian AZ, Knight V, Johnson KM. Acute respiratory diseases of viral etiology. IV. Respiratory syncytial virus. Am J Public Health 1962; 52:918-25.
22. Gupta CK, Leszczynski J, Gupta RK, Siber GR. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 1996; 14:1417-20.
23. Hambling MH. Survival of the respiratory syncytial virus during storage under various conditions. Br J Exp Pathol 1964; 45:647-55.
24. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2005; 2:491-9.
25. Ueba O. Respiratory syncytial virus. I. Concentration and purification of the infectious virus. Acta Med Okayama 1978; 32:265-72.
26. Malley R, Vernacchio L, Devincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Jafri HS, Sanchez PJ, Macdonald K, Montana JB, Thompson CM, Ambrosino DM, Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. Pediatr Infect Dis J 2000; 19:1-7.
27. Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 2006; 24:5839-51.
28. Parasassi T, De Stasio G, Ravagnan G, Rusch RM, Gratton E. Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys J 1991; 60:179-89.
29. Karuppiah N, Sharma A. Cyclodextrins as protein folding aids. Biochem Biophys Res Commun 1995; 211:60-6.
30. Mach H, Middaugh CR. Simultaneous monitoring of the environment of tryptophan, tyrosine, and phenylalanine residues in proteins by near-ultraviolet second-derivative spectroscopy. Anal Biochem 1994; 222:323-31.
31. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 2003; 92:1805-20.
32. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci 2003; 92:218-31.
33. Volkin DB, Burke CJ, Sanyal G, Middaugh CR. Analysis of vaccine stability. Dev Biol Stand 1996; 87:135-42.
34. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006; 95:80-96.
35. Lee JC, Timasheff SN. The stabilization of proteins by sucrose. J Biol Chem 1981; 256:7193-201.
36. Ricker JV, Tsvetkova NM, Wolkers WF, Leidy C, Tablin F, Longo M, Crowe JH. Trehalose maintains phase separation in an air-dried binary lipid mixture. Biophys J 2003; 84:3045-51.